Today: 19 May 2026
Joby Aviation Stock Gets NYC Air Taxi Catalyst as Archer Rivalry Heats Up
27 April 2026
2 mins read

Joby Aviation Stock Gets NYC Air Taxi Catalyst as Archer Rivalry Heats Up

New York, April 27, 2026, 08:03 EDT

Joby Aviation on Monday reported it pulled off New York City’s inaugural point-to-point flights using an electric vertical takeoff and landing air taxi, flying its battery-powered craft from John F. Kennedy International Airport out to Downtown Skyport, then over to the West 30th Street and East 34th Street heliports. These eVTOLs lift straight up like helicopters. According to Joby, that same JFK route—typically a 60- to 120-minute slog by car—would take just seven minutes in the air.

This is what puts the flights squarely on investors’ radar. For Joby, the big hurdle now is shifting the conversation—from talking up prototypes and certification milestones to drilling down on routes, actual noise levels, and whether anyone’s booking rides. Shares traded at $8.50 ahead of Monday’s open, still hanging about 58% below the $20.39 all-time closing high The Motley Fool reported for Aug. 4, 2025.

Joby founder and CEO JoeBen Bevirt called the JFK-to-Manhattan flights a glimpse of “what’s coming” as part of the White House-backed eVTOL Integration Pilot Program, or eIPP. Port Authority Executive Director Kathryn Garcia struck a different chord, describing the flights as “one data point” in the region’s broader review of electric aviation. StreetInsider.com

Joby is stepping up its presence in New York, following its 2025 acquisition of Blade Air Mobility’s passenger business. The deal, valued as high as $125 million according to Reuters, handed Joby access to Blade’s customer base, airport-city logistics expertise, and lounges in New York and other cities. Blade’s key locations at JFK, Newark and Manhattan were also part of the transaction.

Joby flagged 2026 as a potential turning point for its business. Back in February, the company laid out plans to fly its first passengers in Dubai within the year and kick off initial U.S. eIPP operations. Joby projected a $1.4 billion cash and short-term investment balance at the end of 2025, plus a fresh $1.2 billion added in February. “2026 will mark a key inflection point,” CEO Bevirt said. Business Wire

Federal policy has tightened the competition. The FAA and Transportation Department picked eight eIPP projects spanning 26 states. Among them: a Port Authority of New York and New Jersey initiative involving Archer, BETA, Electra, and Joby. The FAA said data from these projects will inform rulemaking for scaling advanced air mobility.

Archer stands out as the closest listed U.S. rival. Back in March, the company set its sights on launching passenger flights in 2026 and announced full FAA acceptance for all its “Means of Compliance”—the benchmarks required to confirm airworthiness. Liquidity ended 2025 at roughly $2 billion. Archer projected a first-quarter adjusted EBITDA loss somewhere between $160 million and $180 million. Archer Aviation

Investor sentiment isn’t where it was. A year back, a 24/7 Wall St. column leaned toward Archer over Joby, but the tables have turned. Joby’s gotten more credit from investors lately, thanks to revenue visibility tied to Blade, while Archer’s still working through certification—commercial momentum hasn’t followed yet.

MarketBeat breaks down the eVTOL landscape as a divide in strategy: Joby wants to run the whole show—aircraft, service, even the customer touchpoints. Archer, on the other hand, brings in big partners like Stellantis and United Airlines. Vertical Aerospace? It’s sticking closer to a classic manufacturer route. So, the field isn’t just about who gets airborne, but who nails the money and the rollout.

The risks here are tough to ignore. Joby hasn’t secured FAA type certification for commercial eVTOL flights, and the Dubai launch date isn’t locked in—delays are possible. Shares also face dilution, hefty spending, and the market’s shifting taste for growth names as rates move. The Motley Fool cautioned that further setbacks might prompt analysts to lower their short-term forecasts.

The demo on Monday stops short of answering if Joby shares are worth buying. What it does do: it surfaces the next hurdle for Joby and rivals—turning a photo-op flight above Manhattan into a certified, reliable, paying operation, instead of one more one-off.

Stock Market Today

  • Medical Facilities (TSX:DR) Sees Price Target Boost Amid Revised Growth and Profit Assumptions
    May 18, 2026, 7:48 PM EDT. Medical Facilities' stock (TSX:DR) attracted renewed investor attention after RBC Capital raised its price target by CA$2 to CA$18.24, aligning with an updated fair value estimate. The broker's bullish outlook is based on higher revenue growth expectations (2.80% vs 1.49%) and improved net profit margin assumptions (7.72% up from 2.61%). However, the future price-to-earnings (P/E) multiple was lowered significantly to 10.22x from 23.38x, while the discount rate rose to 6.35%. Analysts caution that the stock's upside depends on execution against projections, with limited margin for error. Investors are advised to monitor operating trends, capital allocation, and risks to gauge the narrative's evolution.

Latest articles

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.
Agilysys Shares Rise After Earnings Beat

Agilysys Shares Rise After Earnings Beat

19 May 2026
Agilysys shares jumped 16.7% to $81.90 after hours Monday following record fiscal Q4 revenue of $82.9 million and a fiscal 2027 outlook above current sales. Net income for the quarter rose to $12.3 million, or 43 cents a share, from $3.9 million a year earlier. The stock outperformed a weaker tech sector, with the Nasdaq down 0.5%.
Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.

Popular

Why Plug Power Stock Is Falling Today After Its Hydrogen Rally

Why Plug Power Stock Is Falling Today After Its Hydrogen Rally

18 May 2026
Plug Power shares dropped 9.8% to $3.41 in late-morning trading Monday, erasing part of last week’s post-earnings rally. The company reported first-quarter revenue of $163.5 million and improved margins, but posted a net loss of $245.3 million. Investors remain concerned about cash burn and future dilution. Other hydrogen stocks also fell sharply.
Oracle Stock Bulls Just Got a $16 Billion AI Test. Dan Ives Says Wall Street Is Getting It Wrong
Previous Story

Oracle Stock Bulls Just Got a $16 Billion AI Test. Dan Ives Says Wall Street Is Getting It Wrong

Bitcoin Supply Shock? Saylor’s Latest Buy Puts Strategy Ahead Of BlackRock
Next Story

Bitcoin Supply Shock? Saylor’s Latest Buy Puts Strategy Ahead Of BlackRock

Go toTop